MedTrace Logo

MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease

NCT05194163 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-03-29

No results posted yet for this study

Summary

This study is a phase 2a randomized double-blind, placebo-controlled, study, in mild-to-moderate Alzheimer's disease, of the oral investigational drug MW150, a p38alphaMAPK kinase inhibitor. The primary goals of this study are to investigate the safety and tolerability, and drug movements in the body. The secondary goals of the study are to investigate the effects of the drug on cognitive performance, activities of daily living, and behavior, and the biological effects of the drug on blood biomarkers.

Conditions

  • Alzheimer Disease

Interventions

DRUG

MW150

oral-delivered capsule of study drug

DRUG

Placebo

oral delivered capsule matched to study drug capsule

Sponsors & Collaborators

  • Columbia University

    collaborator OTHER

  • National Institute on Aging (NIA)

    collaborator NIH

  • Neurokine Therapeutics

    lead INDUSTRY

Principal Investigators

  • Lawrence S Honig, MD PhD · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2024-08-31
Completion
2024-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05194163 on ClinicalTrials.gov